Lesson of Beyon SCENIC consensus

Patients with Crohn’s disease affecting the colon and ulcerative colitis are known to be at increased risk for the development of dysplasia and colorectal cancer (CRC).1,2 Unlike patients with sporadic CRC, patients with longstanding inflammatory bowel disease (IBD) who develop malignancy do so through different pathophysiologic mechanisms and with foreshortened time frames.3,4 Furthermore, the gross appearance of dysplasia exhibits greater morphologic range in IBD patients, with subtler, flat lesions being commonplace.5 Reassuringly, in the era of biologic therapies, rates of IBD-related CRC and CRC-associated mortality have declined.6 This shift in prevalence has coincided with improved colonoscopic resolution and the adoption of...